Tau aggregates as immunotherapeutic targets

Diana L. Castillo-Carranza, Cristian A. Lasagna-Reeves, Rakez Kayed

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Pathological aggregation of the microtubuleassociated protein tau and accumulation of neurofibrillary tangles (NFT) and other inclusions containing hyperphosphorylated tau are defining histopathological features of Alzheimer disease (AD) and many other neurodegenerative diseases collectively known as tauopathies. The toxicity of tau aggregates has been demonstrated in vitro and in vivo; thus, their clearance by immunotherapy holds clinical promise. Published studies, which are limited in number, have exclusively focused on the clearance of hyperphosphorylated large tau aggregates, e.g., NFT. However, recent studies using human tissues and mouse models have questioned the toxicity and the presumed role of NFT in the progression of tauopathies and challenged the view of tangles as toxic species in the brain. Together, these novel studies have demonstrated that prefilamentous tau oligomers rather than NFT play a crucial role in these disorders. Here, we summarize recent advances in this new field, highlight the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies, and discuss the challenges that lie ahead.

Original languageEnglish (US)
Pages (from-to)426-438
Number of pages13
JournalFrontiers in Bioscience - Scholar
Volume5 S
Issue number2
StatePublished - Jan 1 2013

Fingerprint

Neurofibrillary Tangles
Tauopathies
Oligomers
Toxicity
Neurodegenerative diseases
tau Proteins
Poisons
Brain
Alzheimer Disease
Agglomeration
Tissue
Neurodegenerative Diseases
Immunotherapy
Therapeutics

Keywords

  • Alzheimer disease
  • Clearance
  • Immunotherapy
  • Review
  • Tau oligomers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Castillo-Carranza, D. L., Lasagna-Reeves, C. A., & Kayed, R. (2013). Tau aggregates as immunotherapeutic targets. Frontiers in Bioscience - Scholar, 5 S(2), 426-438.

Tau aggregates as immunotherapeutic targets. / Castillo-Carranza, Diana L.; Lasagna-Reeves, Cristian A.; Kayed, Rakez.

In: Frontiers in Bioscience - Scholar, Vol. 5 S, No. 2, 01.01.2013, p. 426-438.

Research output: Contribution to journalArticle

Castillo-Carranza, DL, Lasagna-Reeves, CA & Kayed, R 2013, 'Tau aggregates as immunotherapeutic targets', Frontiers in Bioscience - Scholar, vol. 5 S, no. 2, pp. 426-438.
Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R. Tau aggregates as immunotherapeutic targets. Frontiers in Bioscience - Scholar. 2013 Jan 1;5 S(2):426-438.
Castillo-Carranza, Diana L. ; Lasagna-Reeves, Cristian A. ; Kayed, Rakez. / Tau aggregates as immunotherapeutic targets. In: Frontiers in Bioscience - Scholar. 2013 ; Vol. 5 S, No. 2. pp. 426-438.
@article{238c243614354ccd9f158d56fb26360c,
title = "Tau aggregates as immunotherapeutic targets",
abstract = "Pathological aggregation of the microtubuleassociated protein tau and accumulation of neurofibrillary tangles (NFT) and other inclusions containing hyperphosphorylated tau are defining histopathological features of Alzheimer disease (AD) and many other neurodegenerative diseases collectively known as tauopathies. The toxicity of tau aggregates has been demonstrated in vitro and in vivo; thus, their clearance by immunotherapy holds clinical promise. Published studies, which are limited in number, have exclusively focused on the clearance of hyperphosphorylated large tau aggregates, e.g., NFT. However, recent studies using human tissues and mouse models have questioned the toxicity and the presumed role of NFT in the progression of tauopathies and challenged the view of tangles as toxic species in the brain. Together, these novel studies have demonstrated that prefilamentous tau oligomers rather than NFT play a crucial role in these disorders. Here, we summarize recent advances in this new field, highlight the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies, and discuss the challenges that lie ahead.",
keywords = "Alzheimer disease, Clearance, Immunotherapy, Review, Tau oligomers",
author = "Castillo-Carranza, {Diana L.} and Lasagna-Reeves, {Cristian A.} and Rakez Kayed",
year = "2013",
month = "1",
day = "1",
language = "English (US)",
volume = "5 S",
pages = "426--438",
journal = "Frontiers in Bioscience - Scholar",
issn = "1945-0516",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - Tau aggregates as immunotherapeutic targets

AU - Castillo-Carranza, Diana L.

AU - Lasagna-Reeves, Cristian A.

AU - Kayed, Rakez

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Pathological aggregation of the microtubuleassociated protein tau and accumulation of neurofibrillary tangles (NFT) and other inclusions containing hyperphosphorylated tau are defining histopathological features of Alzheimer disease (AD) and many other neurodegenerative diseases collectively known as tauopathies. The toxicity of tau aggregates has been demonstrated in vitro and in vivo; thus, their clearance by immunotherapy holds clinical promise. Published studies, which are limited in number, have exclusively focused on the clearance of hyperphosphorylated large tau aggregates, e.g., NFT. However, recent studies using human tissues and mouse models have questioned the toxicity and the presumed role of NFT in the progression of tauopathies and challenged the view of tangles as toxic species in the brain. Together, these novel studies have demonstrated that prefilamentous tau oligomers rather than NFT play a crucial role in these disorders. Here, we summarize recent advances in this new field, highlight the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies, and discuss the challenges that lie ahead.

AB - Pathological aggregation of the microtubuleassociated protein tau and accumulation of neurofibrillary tangles (NFT) and other inclusions containing hyperphosphorylated tau are defining histopathological features of Alzheimer disease (AD) and many other neurodegenerative diseases collectively known as tauopathies. The toxicity of tau aggregates has been demonstrated in vitro and in vivo; thus, their clearance by immunotherapy holds clinical promise. Published studies, which are limited in number, have exclusively focused on the clearance of hyperphosphorylated large tau aggregates, e.g., NFT. However, recent studies using human tissues and mouse models have questioned the toxicity and the presumed role of NFT in the progression of tauopathies and challenged the view of tangles as toxic species in the brain. Together, these novel studies have demonstrated that prefilamentous tau oligomers rather than NFT play a crucial role in these disorders. Here, we summarize recent advances in this new field, highlight the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies, and discuss the challenges that lie ahead.

KW - Alzheimer disease

KW - Clearance

KW - Immunotherapy

KW - Review

KW - Tau oligomers

UR - http://www.scopus.com/inward/record.url?scp=84883242375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883242375&partnerID=8YFLogxK

M3 - Article

VL - 5 S

SP - 426

EP - 438

JO - Frontiers in Bioscience - Scholar

JF - Frontiers in Bioscience - Scholar

SN - 1945-0516

IS - 2

ER -